October 2021 OSE Immunotherapeutics Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of OSE-127
October 2021 OSE Immunotherapeutics Receives Belgian Authorization for a Phase 1 Clinical Trial to Evaluate OSE-127
October 2021 OSE Immunotherapeutics and GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Pancreatic cancer
October 2021 OSE Immunotherapeutics and GERCOR Announce Submission of a Clinical Trial Application for Tedopi®